Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study
Clinical trial published in Scientific reports (2016)
Abstract
We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT. Patients with asymptomatic pulmonary thromboembolism who had not received any other anticoagulant and had received no more than 36 hours of treatment with unfractionated heparin were included. Post RFCA procedure, patients received either rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation; n = 86) or aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation; n = 90). The primary outcome was a composite of LDVT occurrence, change in diameter of femoral veins, and safety outcomes that were analyzed based on major or minor bleeding events. In addition, blood flow velocity was determined. No complete occlusive thrombus or bleeding events were reported with either of the group. The lower incidence rate of non-occluded thrombus in rivaroxaban (5.8%) compared to the aspirin group (16.7%) indicates rivaroxaban may be administered post-RFCA to prevent and treat femoral venous thrombosis in a secure and effective way with a faster inset of action than standard aspirin therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
In Chinese patients undergoing radiofrequency catheter ablation, rivaroxaban (10 mg daily for 14 days) versus aspirin produced no complete occlusive thrombus or bleeding, with fewer non-occlusive femoral thrombi (5.8% versus 16.7%), suggesting rivaroxaban may help prevent post-procedural femoral venous thrombosis.
Context
This prospective, active controlled study evaluated the effectiveness and safety of rivaroxaban versus aspirin in preventing lower extremity deep vein thrombosis (LDVT) in 176 Chinese patients following radiofrequency catheter ablation. The study found that rivaroxaban resulted in a lower incidence of non-occluded thrombus compared to aspirin, without any complete occlusive thrombi or bleeding events. The abstract does not mention leeches, hirudin, or any leech-derived compounds. The research is solely focused on comparing standard pharmaceutical anticoagulants and antiplatelets to manage post-procedural venous thrombosis.
Citation
Reference (Vancouver style)
Li L, Zhang BJ, Zhang BK, Ma J, Liu XZ, Jiang SB. Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study. Sci Rep. 2016;6:28439. doi:10.1038/srep28439. PMID: 27329582
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026